In this compelling video, Professor Vimal discusses the persistent unmet medical needs in Atopic Dermatitis (AD), highlighting that despite the availability of advanced therapies, many patients remain uncontrolled and unsatisfied with current treatment options. He underscores the growing demand for more targeted biologics and introduces Ebglyss, a newly approved IL-13 inhibitor for patients with moderate to severe AD aged 12 and above.
